ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company witnesses ...

We expect investors to focus on the sales performance of ADMA Biologics ’ ADMA portfolio of marketed products and other pipeline updates when it reports fourth-quarter 2024 results. See the ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.

ADMA Biologics, Inc.’s ADMA is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%. The stock has been ...

ADMA Biologics makes products that start out as donated plasma. From the plasma donations, the company extracts immunoglobulin, or antibodies, capable of blocking specific viruses.

ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.

ADMA showed strong growth in 2019, but shares remain 50% off recent highs. ADMA’s outlook for 2020 and beyond appears promising, but it is not without risks.

ADMA Biologics is a plasma pure play This company earns most of its revenue marketing FDA-approved products made from plasma. ADMA Biologics also runs its own plasma collection facilities and ...

To completely resolve this problem, ADMA Biologics acquired Biotest Pharmaceuticals' two manufacturing and testing facilities in Boca Raton, Florida and two FDA approved products, BIVIGAM and Nabi-HB.